Draft:Alimetry

From Wikipedia, the free encyclopedia


Alimetry Limited is a company based in New Zealand which designs, manufactures, and markets wearable medical devices to aid in the diagnosis of gastric dysfunction. The hero product they have is Gastric Alimetry.

Gastric Alimetry[edit]

The Gastric Alimetry test is a pivotal development in gastroenterological diagnostics, utilizing non-invasive methods to gauge gastric electrophysiology in clinical environments. This test, facilitated by a wearable device, leverages body-surface-gastric-mapping technology derived from Electrogastrogram research to record electrophysiological data from the stomach, alongside patient-reported symptoms like nausea, vomiting, abdominal pain, and bloating.[1][2].

Gastric Alimetry records digestive patterns before and after a standard meal, with patients logging symptoms via a dedicated app. The high-resolution data collected is analyzed and delivered through cloud-based technology, providing clinicians with detailed reports to aid in the diagnosis of gastric disorders such as functional dyspepsia and gastroparesis. This method is critical for personalizing therapy for disorders that significantly impact healthcare systems and patients' quality of life [3]

The output of the test is a auto-generated Alimetry Report that clinicians can use to assist with the diagnosis of chronic nausea and vomiting disorders such as Gastroparesis.

Gastric Alimetry received FDA approval[4] and UKCA marking in 2022. The device is currently available for use in the USA, UK, and New Zealand.

Alimetry Ltd[edit]

Alimetry, a pioneering medtech and digital health startup, emerged from the University of Auckland's centre of excellence in digestive diseases in 2019 University of Auckland’s Bioengineering Institute.[5]. Founded by Professor Gregory O’Grady and Dr. Armen Gharibans, the company harnesses a decade of award-winning research to improve care for patients with chronic gastrointestinal symptoms. Alimetry's commitment to leveraging innovative diagnostic solutions aims to transform gastrointestinal health care, enhancing patient outcomes globally.

Alimetry's US-based subsidiary, called Alimetry Inc., was founded in 2022. The subsidiary is based in Minneapolis, MN.

Alimetry Investors[edit]

Alimetry raised its first round of capital in December 2020. In March 2022, Alimetry announced a Series A raise of NZD $16.3 million[6]. The round was led by investment fund Movac, alongside existing investors UniServices, IP Group and Matū Karihi. K1W1 also participated in the round[7]

External Links[edit]

Official Website

References[edit]

  1. ^ "FDA gives green light on medical tool for gut disorders". www.auckland.ac.nz. Retrieved 2023-04-24.
  2. ^ "Alimetry Secures CPT III Reimbursement Code for the Gastric Alimetry Test and Announces Positive Clinical Study Results". Medtech Dive. Retrieved 2024-02-15.
  3. ^ "Alimetry Ltd logo Alimetry Secures CPT III Reimbursement Code for the Gastric Alimetry Test and Announces Positive Clinical Study Results". Medtech Dive. Retrieved 15 Feb 2024.
  4. ^ "K213924 letter" (PDF). FDA.
  5. ^ "FDA gives green light on medical tool for gut disorders - The University of Auckland". www.auckland.ac.nz. Retrieved 2023-04-24.
  6. ^ "'The next F&P Healthcare': Alimetry raises $16m for breakthrough product". NZ Herald. Retrieved 2023-04-24.
  7. ^ "Alimetry Raises $16.3 Million To Launch Wearable Diagnostic Device For The Gut | Scoop News". www.scoop.co.nz. 2 March 2022. Retrieved 2023-04-24.